The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Treating patients with relapsed/refractory myeloma in Ireland
Philip Murphy, MD, Beaumont Hospital, Dublin, Ireland, describes the treatment of younger patients with relapsed/refractory (R/R) multiple myeloma in Ireland. Treatment options for these patients include potentially a second transplant, and/or triplet combination therapy. Using the ESMO guidelines, the challenge for clinicians is to find a suitable combination therapy for patients. This interview was recorded virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
